SAN DIEGO, March 15, 2018 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of patients diagnosed with
cancer, announces that two abstracts have been accepted for poster
presentation at the 2018 American Association for Cancer Research
(AACR) Annual Meeting being held April
14-18, 2018 in Chicago at
McCormick Place North/South.
Details for Biocept's poster presentations are as follows:
Title: Target SelectorTM CTC technology
demonstrates clinical utility in monitoring treatment response in
germ cell tumors (link to abstract)
Session Category/Title: Clinical Research/Liquid Biopsy
Session Date and Time: Wednesday Apr
18, 2018, 8:00 a.m.-12:00 p.m.
CDT
Location: McCormick Place South, Exhibit Hall A, Poster
Section 26
Title: Validation of highly sensitive Target
SelectorTM ctDNA assays for EGFR, BRAF, and KRAS
mutations (link to abstract)
Session Category/Title: Clinical Research/Diagnostic
Biomarkers
Session Date and Time: Tuesday Apr
17, 2018, 1:00 p.m.-5:00 p.m.
CDT
Location: McCormick Place South, Exhibit Hall A, Poster
Section 24, Poster Board #19
"Capturing and analyzing circulating tumor cells (CTCs) with
Biocept's liquid biopsy technology has demonstrated the ability to
correlate CTCs with clinical responses in refractory testicular
cancer," said Shilpa Gupta, MD,
Assistant Professor in the Division of Hematology, Oncology and
Transplantation at Masonic Cancer Center, University of Minnesota. "Refractory testicular
cancers have extremely poor prognosis and novel treatments are
urgently needed to improve outcomes. In our ongoing phase 2 study
of brentuximab vedontin, an anti-CD-30 antibody with bevacizumab in
refractory CD-30 + germ cell tumors, we are utilizing CTCs with
Biocept's liquid biopsy technology both at baseline and serially to
assess correlation with clinical response. The ability of this
technology to detect molecular markers of interest holds promise
for improving the assessment of patients with this disease and
offers a precision medicine based approach to treating these
cancers."
"Our collaboration with the Masonic Cancer Center at
University of Minnesota and the
Huntsman Cancer Center demonstrates proof-of-concept for the use of
our Target Selector™ CTC platform to monitor advanced testicular
cancer," said Biocept's Senior Vice President and Senior Medical
Director Veena Singh, MD. "This not
only exhibits utility in a new tumor type for Biocept, but also
shows the versatility of our antibody cocktail for the capture and
analysis of circulating tumor cells associated with multiple cancer
types. We look forward to advancing our ongoing work with our
collaborators to further demonstrate the clinical utility of our
non-invasive liquid biopsy tests in genitourinary cancer."
"We are pleased to present data at this year's AACR Annual
Meeting highlighting the leading performance of our Target
Selector™ assays and the ability to identify actionable biomarkers
associated with metastatic cancers," said Biocept's President and
CEO Michael Nall. "We believe that
these results add to the body of evidence supporting the analytical
performance and clinical utility of our proprietary molecular
diagnostic technologies, and further solidify our leadership
position in the emerging liquid biopsy segment."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
information for treating and monitoring patients diagnosed with
cancer. The Company's patented Target Selector™ liquid biopsy
technology platform captures and analyzes tumor-associated
molecular markers in both circulating tumor cells (CTCs) and in
plasma (ctDNA). With thousands of tests performed, the
platform has demonstrated the ability to identify cancer mutations
and alterations to inform physicians about a patient's disease and
therapeutic options. For additional information, please visit
www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to our ability to improve the
diagnosis and treatment of cancer, and our ability to advance our
ongoing work with our collaborators to further demonstrate the
clinical utility of our non-invasive liquid biopsy tests, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
View original content with
multimedia:http://www.prnewswire.com/news-releases/biocepts-target-selector-platform-featured-in-two-poster-presentations-at-the-2018-american-association-for-cancer-research-annual-meeting-300614345.html
SOURCE Biocept, Inc.